Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for parp1 protein, human (compound)
Most Correlated Studies
- Expression Analysis Upon PARP-1 or PARG Knockdown in MCF-7 Cells
- Cervical cancer HeLa cells with PARP-1 siRNA knockdown
- PARP-1 KO and wild type T cells following CD3 and CD3/CD28 activation
- Burkitt lymphoma DG-75 cells expressing EBV LMP1 and treated with olaparib
- Hepatocellular carcinoma HepG2 cells with siRNA knockdown of the nuclear protein WEE1
Most Relevant Literature
- Loss of cytidine deaminase expression as a potential attempt to counteract the process of carcinogen…
- From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors.
- Poly (ADP-ribose) Polymerase-1 modulations in the genesis of thrombosis.
- Unraveling the allosteric inhibition mechanism of PARP-1 CAT and the D766/770A mutation effects via …
- PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends.
Most Relevant Clinical Trials
- Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
- Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
- Preoperative Olaparib Endometrial Carcinoma Study (POLEN)
- Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
